Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Passiflora Incarnata Flowering Top
Brand Name
Passiflora Incarnata Kit Refill
Generic Name
Passiflora Incarnata Flowering Top
Active Ingredient
Passiflora Incarnata Flowering TopCategory
Non-Standardized Food Allergenic Extract [EPC]
Variants
2
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Passiflora Incarnata Kit Refill, you must consult a qualified healthcare professional.
Detailed information about Passiflora Incarnata Kit Refill
Passiflora Incarnata Flowering Top is a botanical substance classified primarily as a Non-Standardized Food and Plant Allergenic Extract [EPC], utilized in clinical allergy diagnostics and immunotherapy, as well as traditional therapeutic applications.
The dosage of Passiflora Incarnata Flowering Top varies significantly depending on the clinical indication and the specific formulation used.
Passiflora Incarnata Flowering Top is generally not recommended for use in children under the age of 12 unless specifically directed by a pediatric allergist or specialist.
Patients with significant renal impairment (CrCl < 30 mL/min) should use Passiflora Incarnata Flowering Top with extreme caution. Because it acts as a Phosphate Binder and has renal elimination pathways, accumulation of metabolites could occur. Dose reductions of 50% may be necessary.
In patients with moderate to severe hepatic impairment (Child-Pugh Class B or C), the metabolism of flavonoids and alkaloids may be delayed. Close monitoring of liver function tests (LFTs) is required, and the lowest effective dose should be utilized.
Geriatric patients are more susceptible to the CNS-depressant effects of Passiflora. Initial dosing should start at the low end of the range (e.g., 100 mg to 200 mg) to minimize the risk of dizziness, confusion, and falls.
If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to make up for a missed one, as this increases the risk of adverse CNS effects.
Signs of an overdose of Passiflora Incarnata Flowering Top may include extreme somnolence (sleepiness), severe dizziness, confusion, bradycardia (slow heart rate), and gastrointestinal distress. In severe cases involving high concentrations of alkaloids, tremors or altered mental status may occur.
In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is primarily supportive, focusing on maintaining airway patency and cardiovascular stability.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop taking this medication without medical guidance, especially if being used for allergen immunotherapy.
Most patients tolerate Passiflora Incarnata Flowering Top well, but the following common side effects may occur, particularly during the initiation of therapy:
Passiflora Incarnata Flowering Top is a potent biological agent with significant effects on the central nervous and cardiovascular systems. Patients must be aware that because it is often a "non-standardized" extract, the potency can vary between different manufacturers and batches. This variability increases the risk of unexpected adverse reactions or therapeutic failure.
No FDA black box warnings for Passiflora Incarnata Flowering Top.
Passiflora Incarnata Flowering Top must NEVER be used in the following circumstances:
FDA Category: Not Formally Assigned (Typically avoided). Passiflora Incarnata Flowering Top is considered unsafe for use during pregnancy. The primary concern is the presence of harmala alkaloids, which possess uterine-stimulant properties. Clinical data suggest that these compounds can increase the frequency and intensity of uterine contractions, potentially leading to pregnancy complications. There is insufficient data to determine if it causes structural birth defects, but its pharmacological profile warrants absolute avoidance during all trimesters.
It is not known whether the constituents of Passiflora Incarnata Flowering Top pass into human breast milk. However, many small-molecule alkaloids and flavonoids are excreted in milk. Due to the potential for the infant to experience sedation, poor feeding, or allergic sensitization, the use of Passiflora is generally discouraged while breastfeeding. If use is medically necessary, the infant should be closely monitored for excessive sleepiness.
Passiflora Incarnata Flowering Top exerts its effects through a complex interplay of chemical constituents. Its primary CNS effect is mediated through the GABAergic system. Components like chrysin and other flavonoids bind to the benzodiazepine site of the GABA-A receptor, enhancing the inhibitory effects of GABA.
Additionally, its classification as an Adrenergic alpha-Agonist [MoA] and Adrenergic beta-Agonist [MoA] suggests it interacts with G-protein coupled receptors (GPCRs) in the peripheral and central nervous systems. This can lead to modulation of smooth muscle tone and cardiac output. As a Phosphate Chelating Activity [MoA], the substance contains polyvalent cations or specific organic structures that form insoluble complexes with dietary phosphate in the lumen of the gut, thereby reducing phosphate absorption.
Common questions about Passiflora Incarnata Kit Refill
Passiflora Incarnata Flowering Top is primarily used in clinical settings as a non-standardized allergenic extract for diagnosing and treating plant-based allergies. In traditional medicine, it is widely utilized for its sedative and anxiolytic properties to manage symptoms of anxiety and insomnia. Additionally, it has specialized pharmacological roles as a phosphate binder and an adrenergic agonist. It works by modulating the GABA system in the brain to promote relaxation. Always consult a healthcare provider to determine its appropriateness for your specific medical needs.
The most frequently reported side effects include drowsiness, dizziness, and mild gastrointestinal distress such as nausea or stomach cramps. Because it acts as a central nervous system depressant, many users feel a significant sense of sedation which can impair daily activities. Some individuals may also experience a slight decrease in blood pressure or feelings of confusion. These effects are usually dose-dependent and may decrease as the body becomes accustomed to the extract. If side effects persist or become severe, you should contact your doctor immediately.
No, you should avoid drinking alcohol while using Passiflora Incarnata Flowering Top. Alcohol is also a central nervous system depressant, and combining it with Passiflora can lead to dangerous levels of sedation and respiratory depression. This combination significantly increases the risk of accidents, falls, and severe impairment of motor skills. Even small amounts of alcohol can interact unpredictably with the alkaloids in the flowering top. Always discuss your alcohol consumption habits with your healthcare provider before starting this medication.
Passiflora Incarnata Flowering Top is generally considered unsafe for use during pregnancy and should be avoided. It contains harmala alkaloids, such as harman and harmaline, which have been shown to stimulate uterine contractions. This stimulation could potentially lead to premature labor or other pregnancy complications. There is also insufficient clinical evidence to guarantee the safety of the developing fetus. Pregnant women or those planning to become pregnant should consult their obstetrician for safer alternatives for anxiety or sleep management.
When taken orally, the effects of Passiflora Incarnata Flowering Top typically begin within 30 to 90 minutes. The peak concentration of its active components in the bloodstream usually occurs about 1 to 2 hours after ingestion. For sleep-related issues, it is often recommended to take the dose about an hour before bedtime. The duration of the effect usually lasts between 4 and 6 hours. However, individual response times can vary based on metabolism, age, and whether the medication is taken with food.
While Passiflora is not known to cause severe physical withdrawal symptoms like benzodiazepines, it is best not to stop taking it suddenly if you have been using high doses for a long period. Abruptly stopping may cause 'rebound' symptoms, where the anxiety or insomnia you were treating returns more intensely. A gradual tapering of the dose over one to two weeks is often recommended to allow the nervous system to readjust. Always follow a tapering schedule provided by your healthcare professional. If you experience any severe mood changes upon stopping, seek medical advice.
If you miss a dose, you should take it as soon as you remember, provided it is not almost time for your next scheduled dose. If the next dose is only a few hours away, skip the missed dose and continue with your regular schedule. Never take two doses at once to make up for a missed one, as this can lead to excessive sedation or other side effects. Maintaining a consistent schedule helps keep the levels of the extract stable in your system. If you frequently miss doses, consider using a reminder app or pill organizer.
There is currently no significant clinical evidence to suggest that Passiflora Incarnata Flowering Top causes weight gain. Unlike some pharmaceutical psychotropic medications, it does not typically alter appetite or metabolic rate in a way that leads to fat accumulation. However, because it can cause drowsiness and reduced activity levels, some users might experience minor weight changes if their physical activity decreases significantly. If you notice unusual weight changes while taking this substance, discuss them with your doctor to rule out other causes. Maintaining a balanced diet and regular exercise is always recommended.
Passiflora Incarnata Flowering Top has a high potential for drug interactions and should be used cautiously with other medications. It can significantly increase the effects of other sedatives, anti-anxiety drugs, and antidepressants. There is also a serious risk of interaction with Monoamine Oxidase Inhibitors (MAOIs) due to the presence of harmala alkaloids. It may also interact with blood thinners like warfarin, increasing the risk of bleeding. Always provide your healthcare provider with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are currently taking.
Passiflora Incarnata Flowering Top is a botanical substance, so the term 'generic' applies differently than it does to synthetic drugs. It is available from many different manufacturers as a non-prescription herbal supplement and as a component in various brand-name allergenic extracts. Because it is 'non-standardized,' the quality and concentration of active ingredients can vary significantly between different products. It is important to choose products from reputable manufacturers that follow Good Manufacturing Practices (GMP). For clinical use, your doctor will select a specific, high-quality extract suitable for medical diagnostics.
Other drugs with the same active ingredient (Passiflora Incarnata Flowering Top)
> Warning: Stop taking Passiflora Incarnata Flowering Top and call your doctor immediately if you experience any of these serious symptoms.
Prolonged use of Passiflora Incarnata Flowering Top may lead to the development of tolerance, where higher doses are required to achieve the same sedative effect. There is also a theoretical risk of mild psychological dependence. Long-term use should be monitored for potential impacts on cognitive function and liver health. In the context of its use as a Phosphate Binder, long-term use requires regular monitoring of mineral metabolism to prevent hypophosphatemia (abnormally low phosphate levels).
No FDA black box warnings currently exist for Passiflora Incarnata Flowering Top. However, it is important to note that as a Non-Standardized Allergenic Extract, it carries an inherent risk of severe systemic allergic reactions when used in diagnostic testing or immunotherapy. These procedures should only be performed in clinical settings equipped with emergency resuscitation equipment, including epinephrine.
Report any unusual symptoms or persistent side effects to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.
Healthcare providers may require the following tests during treatment:
Passiflora Incarnata Flowering Top frequently causes drowsiness and may impair your physical coordination and reaction time. Do not drive, operate heavy machinery, or engage in hazardous activities until you know how this medication affects you. The risk of impairment is significantly increased if combined with alcohol or other sedatives.
Alcohol consumption should be strictly avoided or significantly limited while taking Passiflora Incarnata Flowering Top. Alcohol synergistically increases the sedative effects of the extract, which can lead to dangerous levels of respiratory depression and impaired motor control.
While Passiflora does not typically cause a severe withdrawal syndrome, sudden discontinuation after long-term, high-dose use may result in "rebound" anxiety or insomnia. It is generally recommended to taper the dose over a period of 1 to 2 weeks under the guidance of a healthcare professional.
> Important: Discuss all your medical conditions, including any history of depression, heart disease, or liver problems, with your healthcare provider before starting Passiflora Incarnata Flowering Top.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as the complex chemistry of Passiflora Incarnata Flowering Top creates a high potential for multi-drug interactions.
Conditions requiring a careful risk-benefit analysis by a healthcare provider:
Patients who are allergic to certain fruits or other botanical extracts may exhibit cross-sensitivity to Passiflora Incarnata Flowering Top. This includes potential reactions in individuals sensitive to:
> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to botanical products, before prescribing or administering Passiflora Incarnata Flowering Top.
Elderly patients (65 years and older) are at an increased risk for adverse effects from Passiflora Incarnata Flowering Top. Age-related declines in renal and hepatic function can lead to higher systemic concentrations of the extract. The most significant concern in this population is the increased risk of falls due to ataxia and sedation. Healthcare providers should initiate treatment at the lowest possible dose and monitor for cognitive impairment.
In patients with impaired kidney function, the excretion of metabolites is slowed. Furthermore, the substance's role as a Phosphate Binder and Chelating Agent can significantly alter mineral homeostasis in patients with chronic kidney disease (CKD). Dosing should be adjusted based on the Glomerular Filtration Rate (GFR), and serum phosphate levels must be checked regularly.
Because the liver is the primary site for the metabolism of the flavonoids and alkaloids found in Passiflora, patients with hepatic impairment are at risk for toxicity. Usage is contraindicated in severe liver disease and should be used with extreme caution in mild-to-moderate cases, with frequent monitoring of liver enzymes (ALT, AST).
> Important: Special populations require individualized medical assessment. Always consult with a specialist before administering this substance to vulnerable groups.
| Parameter | Value |
|---|---|
| Bioavailability | 5% - 12% (Oral) |
| Protein Binding | 60% - 75% |
| Half-life | 2 - 5 hours |
| Tmax | 1 - 2 hours |
| Metabolism | Hepatic (Glucuronidation, CYP3A4) |
| Excretion | Renal (approx. 70%), Fecal (approx. 20%) |
Passiflora Incarnata Flowering Top belongs to the therapeutic class of Non-Standardized Plant Allergenic Extracts. It is also grouped under Central Nervous System Agents and Phosphate Binders depending on the specific clinical application. Related substances include Valeriana officinalis and Humulus lupulus, though Passiflora has a unique pharmacological profile due to its specific alkaloid content.